| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e8902b26da143e3ca1c4eeb1a8843690 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16121
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16162 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04 |
| filingDate |
2021-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4402f27878ab05abffcaaae5adb3540a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49b21fefb20956ab130777a857aed3c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe298dd34942bb467f3df3583b352380
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a20090ddbb9e23fede063cb8aaa4692d |
| publicationDate |
2022-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022127705-A1 |
| titleOfInvention |
Compositions immunogenic against influenza and sars coronavirus 2, methods of making and using thereof |
| abstract |
Live attenuated viruses for protection against the novel coronavirus Sars-CoV-2 are provided. The live attenuated chimeric virus strains are based on a live attenuated influenza A or B virus (LAIVA/B), used a master backbone, which includes deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1), engineered to express one or more antigens of the Sars-CoV-2 (herein, CoV2Ag). The chimeric virus strain is referred to generally herein, as DelNS1-A/B-Sars-CoV-2-CoV2Ag. The DelNS1-A/B-Sars-CoV-2-CoV2Ag strain preferably shows spontaneous cold adaption with preference to grow at 30-33℃. Compositions including the chimeric virus also provided as a co-composition with a LAIVA/B. The DelNS1-A/B-Sars-CoV-2-CoV2Ag strain can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2. The co-compositions can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2 and influenza A and/or B. |
| priorityDate |
2020-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |